24,243 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Purchased by HealthInvest Partners AB

HealthInvest Partners AB purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 24,243 shares of the company's stock, valued at approximately $1,226,000. Ionis Pharmaceuticals makes up 1.0% of HealthInvest Partners AB's holdings, making the stock its 26th largest holding.

Several other large investors have also recently added to or reduced their stakes in the company. Tennessee Valley Asset Management Partners bought a new position in Ionis Pharmaceuticals in the 4th quarter valued at $34,000. Peoples Bank KS acquired a new position in Ionis Pharmaceuticals during the 3rd quarter worth about $39,000. Almanack Investment Partners LLC. bought a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $44,000. Quantbot Technologies LP bought a new stake in Ionis Pharmaceuticals during the 2nd quarter worth about $44,000. Finally, Captrust Financial Advisors increased its position in Ionis Pharmaceuticals by 21.1% in the 2nd quarter. Captrust Financial Advisors now owns 1,429 shares of the company's stock valued at $53,000 after acquiring an additional 249 shares in the last quarter. 93.86% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IONS has been the subject of several research analyst reports. Oppenheimer boosted their price objective on shares of Ionis Pharmaceuticals from $72.00 to $75.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 9th. Royal Bank of Canada boosted their target price on Ionis Pharmaceuticals from $65.00 to $70.00 and gave the stock an "outperform" rating in a research report on Friday, January 26th. Piper Sandler raised their price target on Ionis Pharmaceuticals from $62.00 to $63.00 and gave the company an "overweight" rating in a report on Thursday, February 22nd. Needham & Company LLC reissued a "buy" rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Tuesday, April 9th. Finally, Wolfe Research upgraded shares of Ionis Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $58.00 target price on the stock in a research report on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.08.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ:IONS traded down $0.01 during trading on Tuesday, hitting $41.54. 1,065,939 shares of the company's stock traded hands, compared to its average volume of 1,160,321. The company has a 50-day moving average price of $44.58 and a 200-day moving average price of $47.42. Ionis Pharmaceuticals, Inc. has a 52 week low of $34.32 and a 52 week high of $54.44. The company has a current ratio of 5.90, a quick ratio of 5.83 and a debt-to-equity ratio of 3.18.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.72. The firm had revenue of $325.00 million for the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. The company's quarterly revenue was up 113.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.37) earnings per share. Equities analysts expect that Ionis Pharmaceuticals, Inc. will post -4 EPS for the current year.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, EVP Onaiza Cadoret-Manier sold 5,564 shares of the firm's stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $50.42, for a total transaction of $280,536.88. Following the completion of the sale, the executive vice president now directly owns 33,810 shares in the company, valued at $1,704,700.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 10,773 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $52.00, for a total value of $560,196.00. Following the completion of the transaction, the executive vice president now directly owns 32,516 shares of the company's stock, valued at approximately $1,690,832. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Onaiza Cadoret-Manier sold 5,564 shares of the stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $50.42, for a total value of $280,536.88. Following the sale, the executive vice president now directly owns 33,810 shares in the company, valued at $1,704,700.20. The disclosure for this sale can be found here. Insiders sold a total of 93,734 shares of company stock valued at $4,724,226 over the last ninety days. 2.65% of the stock is currently owned by company insiders.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.